Health and Medicine

Vials with medication and syringe on blue methacrylate table. Horizontal composition. Top elevated view.

VUMC studies provide key positive results for COVID-19 vaccine in early-stage clinical trial

An experimental coronavirus vaccine stimulated robust immune responses against SARS-CoV-2, the virus that causes COVID-19, and raised no serious safety concerns in an early-stage clinical trial.

New tools to study bioactive lipids

Vanderbilt researchers have identified and characterized inhibitors of an enzyme that synthesizes lipid signaling molecules with roles in energy balance, inflammation and addiction.

“Nur” target may aid arthritis treatment

Vanderbilt immunologists have discovered that the protein Nur77 is part of a control mechanism that guards against autoimmunity in natural killer T cells.

New study supports remdesivir as COVID-19 treatment

This week researchers at Vanderbilt University Medical Center (VUMC), the University of North Carolina at Chapel Hill and Gilead Sciences reported that remdesivir potently inhibited SARS-CoV-2, the virus which causes COVID-19, in human lung cell cultures and that it improved lung function in mice infected with the virus.

Recurrent UTIs linked to hidden reservoir

Bacterial invasion of vaginal cells sets up a protective niche and a reservoir for recurrent urinary tract infections, Vanderbilt researchers demonstrated.

Jeff Balser, MD, PhD, left, Jennifer Pietenpol, PhD, and Eric Skaar, PhD, pose for a photo during a recent tour of new space for the Vanderbilt Institute for Infection, Immunology and Inflammation.

New space bolsters infectious disease and immunology discovery

The Vanderbilt Institute for Infection, Immunology and Inflammation (VI4) recently moved into its new research and administrative home.

1 46 47 48 49 50 197